Compare XOS & IXHL Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | XOS | IXHL |
|---|---|---|
| Founded | 2016 | 2001 |
| Country | United States | Australia |
| Employees | N/A | N/A |
| Industry | Construction/Ag Equipment/Trucks | |
| Sector | Consumer Discretionary | |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 38.1M | 35.4M |
| IPO Year | 2020 | 2024 |
| Metric | XOS | IXHL |
|---|---|---|
| Price | $1.56 | $1.87 |
| Analyst Decision | Buy | |
| Analyst Count | 2 | 0 |
| Target Price | $4.00 | ★ $18.18 |
| AVG Volume (30 Days) | ★ 102.4K | 93.8K |
| Earning Date | 11-12-2026 | 11-12-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 59.49 | N/A |
| EPS | N/A | ★ N/A |
| Revenue | ★ $45,992,000.00 | $12,000.00 |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | $90.13 | N/A |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | N/A | ★ N/A |
| 52 Week Low | $1.58 | $0.16 |
| 52 Week High | $8.27 | $6.39 |
| Indicator | XOS | IXHL |
|---|---|---|
| Relative Strength Index (RSI) | 23.98 | 28.52 |
| Support Level | N/A | $0.16 |
| Resistance Level | $1.89 | $3.87 |
| Average True Range (ATR) | 0.24 | 0.21 |
| MACD | -0.08 | -0.02 |
| Stochastic Oscillator | 2.51 | 21.89 |
Xos Inc is a fleet electrification solutions provider committed to the decarbonization of commercial transportation. Xos designs and manufactures Class 5 through 8 battery-electric commercial vehicles that travel on last-mile, back-to-base routes of up to 200 miles per day. Xos also offers charging infrastructure products and services through Xos Energy Solutions to support electric vehicle fleets. Its products include Stepvan, MDXT, HDXT, Xosphere, and Xos Energy Solutions.
Incannex Healthcare Inc is a clinical-stage biopharmaceutical development company dedicated to developing inventive medicines for patients living with serious chronic diseases and unmet needs. The Company's drug candidates include IHL-42X for the treatment of obstructive sleep apnea (OSA) and PSX-001, the Company's psilocybin treatment in combination with psychological therapy in development to treat patients with generalized anxiety disorder (GAD). The Company also has a drug candidate, IHL-675A, for the treatment of rheumatoid arthritis. Each of these programs target conditions that currently have limited, inadequate, or no approved pharmaceutical treatment options. The Company continues to evaluate strategies for IHL-675A when and as resources permit.